Log In
Print this Print this

Montelukast/Levocetirizine (HCP1102)

  Manage Alerts
Collapse Summary General Information
Company Hanmi Pharmaceutical Co. Ltd.
DescriptionFixed dose combination of Montelukast / Levocetirizine
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentPhase III
Standard IndicationRhinitis
Indication DetailsTreat perennial allergic rhinitis (PAR)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today